secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023520
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENSAR Q3 2022 revenue down 6% to $7.7M; net loss narrows to $4.0M; launches ALLY system
--------------------------------------------------------------------------------

- Revenue $7.7M, down 6% YoY; U.S. procedure volume up 9%, offset by South Korean reimbursement challenges.
- Net loss of $4.0M (-$0.39 per share) improved from $6.2M loss (-$0.65) in Q3 2021; Adjusted EBITDA -$1.6M.
- Launched ALLY Adaptive Cataract Treatment System in the U.S. in August 2022; first installations with positive surgeon feedback.
- R&D expenses dropped 50% to $1.6M as ALLY development costs capitalized after June 2022 clearance.
- Approximately 88% of revenue from recurring sources; worldwide procedure volume 28,453 in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000095017022023520/0000950170-22-023520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000095017022023520/lnsr-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer